(2S,3R,4S,5R,6R)-3-(氰基甲氧基)-4,5-二羟基-6-(羟基甲基)四氢-2H-吡喃-2-硫醇 | 61145-34-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (2S,3R,4S,5R,6R)-3-(氰基甲氧基)-4,5-二羟基-6-(羟基甲基)四氢-2H-吡喃-2-硫醇
• 英文名称: cyanomethyl-1-thiogalactoside
• 英文别名: β-D-Gal-(1<*>O)-SCH2CN；cyanomethyl 1-thio-β-D-galactopyranoside；Cyanomethyl-1-thio-β-D-galactopyranosid；Cyanomethyl-1-thio-B-D-galactopyranoside；2-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylacetonitrile
• CAS: 61145-34-4
• 化学式: C₈H₁₃NO₅S
• 分子量: 235.261
• InChiKey: SUMVMYXGZNTTJM-HNEXDWKRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  139
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  甲醇 、 (2S,3R,4S,5R,6R)-3-(氰基甲氧基)-4,5-二羟基-6-(羟基甲基)四氢-2H-吡喃-2-硫醇 在 sodium 作用下， 反应 64.0h， 生成 2-imino-2-methoxyethyl-1-thiogalactoside
  参考文献：
  名称：

  Direct aqueous synthesis of cyanomethyl thioglycosides from reducing sugars; ready access to reagents for protein glycosylation

  摘要：

  未保护的碳水化合物可以直接转化为氰乙基硫代糖苷，然后可以通过与2-氯-1,3-二甲基咪唑氯化铵（DMC）和硫代乙腈在水溶液中反应的方式，完全立体选择性地用于蛋白质糖基化。

  DOI：

  10.1039/c6ob01069e
• 作为产物：
  描述：

  D-吡喃葡萄糖 、 2-mercaptoacetonitrile 在 2-氯-1,3-二甲基氯化咪唑啉 、 三乙胺 作用下， 以 水 为溶剂， 反应 0.5h， 以41%的产率得到(2S,3R,4S,5R,6R)-3-(氰基甲氧基)-4,5-二羟基-6-(羟基甲基)四氢-2H-吡喃-2-硫醇
  参考文献：
  名称：

  Direct aqueous synthesis of cyanomethyl thioglycosides from reducing sugars; ready access to reagents for protein glycosylation

  摘要：

  未保护的碳水化合物可以直接转化为氰乙基硫代糖苷，然后可以通过与2-氯-1,3-二甲基咪唑氯化铵（DMC）和硫代乙腈在水溶液中反应的方式，完全立体选择性地用于蛋白质糖基化。

  DOI：

  10.1039/c6ob01069e

文献信息

• AGENTS FOR CLEARING BIOMOLECULES FROM CIRCULATION
  申请人：Rossin Raffaella

  公开号：US20130272959A1

  公开（公告）日：2013-10-17

  Described is a method, and a combination of agents for used therein, by which an agent administered to a subject can be rapidly cleared from circulation. This is achieved by providing an Administration Agent (e.g. a probe for pretargeting) with a reactive group and providing a Clearing Agent with another reactive group, said reactive groups forming a bio-orthogonally reactive pair. Preferably, the reactive pair comprises a cyclooctene or cyclooctyn as one reactant, and a diene as the other reactant. The method and combination can be used for the removal of any bindable molecule from circulation, such as an excess of a pre-targeting probe in the course of a pre-targeting method, a targeting or imaging agent delivered, or the removal of any biomolecule already present in circulation.

  描述了一种方法，以及其中使用的一组药剂组合，通过该方法，可以迅速清除给予受试者的药剂在循环中的存在。这是通过提供具有反应基团的给药剂（例如，用于预先靶向的探针）和提供具有另一种反应基团的清除剂来实现的，所述反应基团形成生物正交反应对。最好，反应对包括环辛烯或环辛炔作为一种反应物，二烯作为另一种反应物。该方法和组合可用于从循环中去除任何可结合分子，例如，在预先靶向方法中清除探针的过量，传递的靶向或成像剂，或已存在于循环中的任何生物分子的清除。
• POLYPEPTIDE DERIVATIVES AND NUCLEIC ACID CARRIERS CONTAINING THE SAME
  申请人：HISAMITSU PHARMACEUTICAL CO., INC.

  公开号：EP1285942A1

  公开（公告）日：2003-02-26

  There are disclosed polypeptide derivatives and their pharmaceutically acceptable salts represented by formula (1), as well as their utility as nucleic acid carriers in gene therapy.

  本文公开了由式（1）表示的多肽衍生物及其药学上可接受的盐，以及它们在基因治疗中作为核酸载体的用途。
• Akamatsu, Ken; Yamasaki, Yasuomi; Nishikawa, Makiya, Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 290, # 3, p. 1242 - 1249
  作者：Akamatsu, Ken、Yamasaki, Yasuomi、Nishikawa, Makiya、Takakura, Yoshinobu、Hashida, Mitsuru

  DOI：——

  日期：——
• ——
  作者：Hideki Hirabayashi、Makiya Nishikawa、Yoshinobu Takakura、Mitsuru Hashida

  DOI：10.1023/a:1016053128569

  日期：——

  Purpose. A biodegradable carrier for the liver-specific delivery of drugs was developed using poly-l-glutamic acid (PLGA) modified with galactose (galactosylated PLGA or Gal-PLGA), and its feasibility was investigated in mice.Methods. In-111-PLGA and In-111-Gal-PLGAs were injected in mice and their distribution and biodegradation properties were studied.Results. After intravenous injection, In-111-PLGA was rapidly eliminated from the plasma and recovered mainly in the kidneys and urine. Approximately 15% of the dose was recovered in the liver, predominantly in the nonparenchymal cells. In-111-Gal-PLGAs were taken up by the liver parenchymal cells. Derivatives having 16 or more galactose residues were taken up by the liver to a higher extent ( > 60% of the dose). The hepatic clearance of In-111-Gal-PLGAs correlated with their number of galactose residues. In-111-Gal(18)-PLGA was degraded into low-molecular weight products in the liver.Conclusions. The advantageous in vivo properties of Gal-PLGA as a liver-specific biodegradable carrier of drugs were demonstrated in mice.
• Polypeptide derivatives and nucleic acid carriers containing the same
  申请人：——

  公开号：US20040005708A1

  公开（公告）日：2004-01-08

  There are disclosed polypeptide derivatives and their pharmaceutically acceptable salts represented by formula (1), as well as their utility as nucleic acid carriers in gene therapy. 1